Minneapolis, MN,July 11, 2016(GLOBE NEWSWIRE) --
Dr. Michael Sterns Joins PetVivo Advisory Board
MINNEAPOLIS, MN July 11, 2016 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for pets is very pleased to announce that Michael Sterns, DVM has joined the PetVivo Veterinary Advisory Board. Dr. Sterns brings PetVivo more than thirty years of clinical and commercial experience in the veterinary field.
Dr. Sterns earned his BS in Biological Sciences (magna cum laude, Phi Beta Kappa) from the University of Southern California in 1980. After graduating from the UC Davis School of Veterinary Medicine in 1984, he began his career as an Equine Veterinarian. Dr. Sterns earned his MBA from the Haas School of Business at UC Berkeley in 1990, and spent the next twenty-three years raising greater than $200 million in private and public equity, negotiating licensing deals, and building start-ups in human and veterinary therapeutics, medical devices and research tools.
Dr. Sterns returned to clinical practice in 2012, and is now a mobile Veterinaruan with VetPronto, a san Francisco Bay Area start up, and also practices part time general small animal medicine and surgery at Alta View Animal Hospital in Mountain View, California.
“We are extremely pleased to have Dr. Sterns join our Advisory Board,” commented PetVivo’s CEO John Lai, “Michael brings a unique blend of large and small animal practice experience in addition to extensive industry experience to help guide PetVivo’s growth.”
PetVivo’s lead product, Kush Canine, a Veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is available for sale in limited quantities to key opinion leaders, with a targeted launch slated for later this year.
You can learn more about Kush Canine and PetVivo by visiting the companies website at www.petvivo.com
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
PetVivo’s Corporate Presentation can be found here:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
Chief Executive Officer
PetVivo Holdings, Inc.
Source:Petvivo Holdings, Inc.